2-Fluoro-5-nitro-6-phenyl-3-pyridin-3-ylpyridine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 2-Fluoro-5-nitro-6-phenyl-3-pyridin-3-ylpyridine
• 英文别名: 2-fluoro-5-nitro-6-phenyl-3-pyridin-3-ylpyridine
• 化学式: C16H10FN3O2
• 分子量: 295.27
• InChiKey: TWBZTQUQPIOKJW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  22
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  71.6
• 氢给体数：
  0
• 氢受体数：
  5

文献信息

• CARBOLINE AND CARBAZOLE BASED IMAGING AGENTS FOR DETECTING NEUROLOGICAL DYSFUNCTION
  申请人：Eli Lilly and Company

  公开号：EP2852572A1

  公开（公告）日：2015-04-01
• [EN] CARBOLINE AND CARBAZOLE BASED IMAGING AGENTS FOR DETECTING NEUROLOGICAL DYSFUNCTION<br/>[FR] AGENTS D'IMAGERIE À BASE DE CARBOLINE ET DE CARBAZOLE POUR LA DÉTECTION DE DYSFONCTION NEUROLOGIQUE
  申请人：LILLY CO ELI

  公开号：WO2013176698A1

  公开（公告）日：2013-11-28

  Disclosed here in are compounds and methods of diagnosing Alzheimer's Disease or a predisposition thereto in a mammal, the method comprising administering to the mammal a diagnostically effective amount of a radiolabeled compound, allowing the com¬ pound to distribute into the brain tissue, and imaging the brain tissue, wherein an increase in binding of the compound to the brain tissue compared to a normal control level of binding indicates that the mammal mal is suffering from or is at risk of developing Alzheimer's Disease. The claimed compounds have the structure of formula (I) wherein: L is N or CR5, M is N or CR6; P is N or CR7; and Q is N or CR8; X is a bond or is Cl-14alkyl, wherein at least one carbon is optionally replaced by C(O), 0, S, S02, or NH, NH-Cl-8alkyl, and wherein at least one H of Cl-8alkyl is optionally replaced by halo, OH, Cl-6alkyl; wherein at least one halo is optionally replaced with a radionuclide or a fluorescent tag. The other variables are as defined in the claims.